

Nanexa filing complaint of patent infringement

Nanexa AB (publ) today announces that the company has filed a complaint of patent infringement against the American company VitriVax Inc.

On May 27, 2021, Nanexa filed a complaint of patent infringement in the United States District Court of Delaware against VitriVax Inc. In the lawsuit, Nanexa has asserted three of its U.S. patents related to its drug delivery platform PharmaShell®. Nanexa seeks both damages and an injunction preventing VitriVax's continued use of the technology.

"We are doing this to protect the significant investments we have made in our industry-leading technology," said David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa filing complaint of patent infringement](#)